Endometrial cancer with progestagen and oestrogen oral contraceptives

The Collaborative Group's meta-analysis of 36 epidemiological studies published from 1987 to 2014 claims that oral contraceptives prevent endometrial cancer.1 The median age of 27 276 women developing endometrial cancer was 63 years when most oral contraceptive use is long past but recent use o...

Full description

Saved in:
Bibliographic Details
Published in:The lancet oncology 2015-11, Vol.16 (15), p.e527-e527
Main Author: Grant, Ellen C G
Format: Article
Language:English
Subjects:
Birth control
Breast cancer
Contraceptives, Oral - adverse effects
Endometrial cancer
Endometrial Neoplasms - epidemiology
Estrogens - adverse effects
Female
Health risk assessment
Hematology, Oncology and Palliative Medicine
Humans
Progestins - adverse effects
Womens health
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c4438-7c970c084d5a80ec567b95bfe15c6343ba0ee16c51a40f9babe04cc0e4db87533
cites cdi_FETCH-LOGICAL-c4438-7c970c084d5a80ec567b95bfe15c6343ba0ee16c51a40f9babe04cc0e4db87533
container_end_page e527
container_issue 15
container_start_page e527
container_title The lancet oncology
container_volume 16
creator Grant, Ellen C G
description The Collaborative Group's meta-analysis of 36 epidemiological studies published from 1987 to 2014 claims that oral contraceptives prevent endometrial cancer.1 The median age of 27 276 women developing endometrial cancer was 63 years when most oral contraceptive use is long past but recent use of hormones for menopause or breast cancer therapy is more likely.
doi_str_mv 10.1016/S1470-2045(15)00278-8
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1751203132</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>1_s2_0_S1470204515002788</els_id><sourcerecordid>3860725221</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4438-7c970c084d5a80ec567b95bfe15c6343ba0ee16c51a40f9babe04cc0e4db87533</originalsourceid><addsrcrecordid>eNqNkU1v1DAQhi0Eoh_wE0CRuLSHwExsx84FhKrlQ6rEAThbjjNbXLL2YmeL-u9xkgJSL3CyPXr8eMYvY88QXiJg--ozCgV1A0KeoTwHaJSu9QN2XMqilkLrh8t-RY7YSc7XAKgQ5GN21LRSSM31MdtswhB3NCVvx8rZ4ChVP_30rdqneEV5slcUKhuGKpbDXApVTDMaw5Sso_3kbyg_YY-2dsz09G49ZV_fbb5cfKgvP73_ePH2snZCcF0r1ylwoMUgrQZyslV9J_stoXQtF7y3QIStk2gFbLve9gTCOSAx9FpJzk_Z2eot3f04lI7MzmdH42gDxUM2qCQ2wJE3_4FyVEXazeiLe-h1PKRQBlkojR1yXSi5Ui7FnBNtzT75nU23BsHMkZglEjP_t0FplkjMfO_5nf3Q72j4c-t3BgV4swJUfu7GUzLZeSpJDD6Rm8wQ_T-feH3P4EYfvLPjd7ql_HcakxsDq2R2oFwMmv8Crz-u0Q</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1731819138</pqid></control><display><type>article</type><title>Endometrial cancer with progestagen and oestrogen oral contraceptives</title><source>Elsevier</source><creator>Grant, Ellen C G</creator><creatorcontrib>Grant, Ellen C G</creatorcontrib><description>The Collaborative Group's meta-analysis of 36 epidemiological studies published from 1987 to 2014 claims that oral contraceptives prevent endometrial cancer.1 The median age of 27 276 women developing endometrial cancer was 63 years when most oral contraceptive use is long past but recent use of hormones for menopause or breast cancer therapy is more likely.</description><identifier>ISSN: 1470-2045</identifier><identifier>EISSN: 1474-5488</identifier><identifier>DOI: 10.1016/S1470-2045(15)00278-8</identifier><identifier>PMID: 26545838</identifier><identifier>CODEN: LANCAO</identifier><language>eng</language><publisher>England: Elsevier Ltd</publisher><subject>Birth control ; Breast cancer ; Contraceptives, Oral - adverse effects ; Endometrial cancer ; Endometrial Neoplasms - epidemiology ; Estrogens - adverse effects ; Female ; Health risk assessment ; Hematology, Oncology and Palliative Medicine ; Humans ; Progestins - adverse effects ; Womens health</subject><ispartof>The lancet oncology, 2015-11, Vol.16 (15), p.e527-e527</ispartof><rights>Elsevier Ltd</rights><rights>2015 Elsevier Ltd</rights><rights>Copyright Elsevier Limited Nov 2015</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4438-7c970c084d5a80ec567b95bfe15c6343ba0ee16c51a40f9babe04cc0e4db87533</citedby><cites>FETCH-LOGICAL-c4438-7c970c084d5a80ec567b95bfe15c6343ba0ee16c51a40f9babe04cc0e4db87533</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27903,27904</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/26545838$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Grant, Ellen C G</creatorcontrib><title>Endometrial cancer with progestagen and oestrogen oral contraceptives</title><title>The lancet oncology</title><addtitle>Lancet Oncol</addtitle><description>The Collaborative Group's meta-analysis of 36 epidemiological studies published from 1987 to 2014 claims that oral contraceptives prevent endometrial cancer.1 The median age of 27 276 women developing endometrial cancer was 63 years when most oral contraceptive use is long past but recent use of hormones for menopause or breast cancer therapy is more likely.</description><subject>Birth control</subject><subject>Breast cancer</subject><subject>Contraceptives, Oral - adverse effects</subject><subject>Endometrial cancer</subject><subject>Endometrial Neoplasms - epidemiology</subject><subject>Estrogens - adverse effects</subject><subject>Female</subject><subject>Health risk assessment</subject><subject>Hematology, Oncology and Palliative Medicine</subject><subject>Humans</subject><subject>Progestins - adverse effects</subject><subject>Womens health</subject><issn>1470-2045</issn><issn>1474-5488</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2015</creationdate><recordtype>article</recordtype><recordid>eNqNkU1v1DAQhi0Eoh_wE0CRuLSHwExsx84FhKrlQ6rEAThbjjNbXLL2YmeL-u9xkgJSL3CyPXr8eMYvY88QXiJg--ozCgV1A0KeoTwHaJSu9QN2XMqilkLrh8t-RY7YSc7XAKgQ5GN21LRSSM31MdtswhB3NCVvx8rZ4ChVP_30rdqneEV5slcUKhuGKpbDXApVTDMaw5Sso_3kbyg_YY-2dsz09G49ZV_fbb5cfKgvP73_ePH2snZCcF0r1ylwoMUgrQZyslV9J_stoXQtF7y3QIStk2gFbLve9gTCOSAx9FpJzk_Z2eot3f04lI7MzmdH42gDxUM2qCQ2wJE3_4FyVEXazeiLe-h1PKRQBlkojR1yXSi5Ui7FnBNtzT75nU23BsHMkZglEjP_t0FplkjMfO_5nf3Q72j4c-t3BgV4swJUfu7GUzLZeSpJDD6Rm8wQ_T-feH3P4EYfvLPjd7ql_HcakxsDq2R2oFwMmv8Crz-u0Q</recordid><startdate>201511</startdate><enddate>201511</enddate><creator>Grant, Ellen C G</creator><general>Elsevier Ltd</general><general>Elsevier Limited</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>0TZ</scope><scope>3V.</scope><scope>7RV</scope><scope>7TO</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8C2</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>H94</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>M1P</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope></search><sort><creationdate>201511</creationdate><title>Endometrial cancer with progestagen and oestrogen oral contraceptives</title><author>Grant, Ellen C G</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4438-7c970c084d5a80ec567b95bfe15c6343ba0ee16c51a40f9babe04cc0e4db87533</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2015</creationdate><topic>Birth control</topic><topic>Breast cancer</topic><topic>Contraceptives, Oral - adverse effects</topic><topic>Endometrial cancer</topic><topic>Endometrial Neoplasms - epidemiology</topic><topic>Estrogens - adverse effects</topic><topic>Female</topic><topic>Health risk assessment</topic><topic>Hematology, Oncology and Palliative Medicine</topic><topic>Humans</topic><topic>Progestins - adverse effects</topic><topic>Womens health</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Grant, Ellen C G</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Pharma and Biotech Premium PRO</collection><collection>ProQuest Central (Corporate)</collection><collection>ProQuest Nursing and Allied Health Journals</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>Lancet Titles</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Nursing &amp; Allied Health Database (Alumni Edition)</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>PML(ProQuest Medical Library)</collection><collection>Nursing &amp; Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><jtitle>The lancet oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Grant, Ellen C G</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Endometrial cancer with progestagen and oestrogen oral contraceptives</atitle><jtitle>The lancet oncology</jtitle><addtitle>Lancet Oncol</addtitle><date>2015-11</date><risdate>2015</risdate><volume>16</volume><issue>15</issue><spage>e527</spage><epage>e527</epage><pages>e527-e527</pages><issn>1470-2045</issn><eissn>1474-5488</eissn><coden>LANCAO</coden><abstract>The Collaborative Group's meta-analysis of 36 epidemiological studies published from 1987 to 2014 claims that oral contraceptives prevent endometrial cancer.1 The median age of 27 276 women developing endometrial cancer was 63 years when most oral contraceptive use is long past but recent use of hormones for menopause or breast cancer therapy is more likely.</abstract><cop>England</cop><pub>Elsevier Ltd</pub><pmid>26545838</pmid><doi>10.1016/S1470-2045(15)00278-8</doi><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1470-2045
ispartof The lancet oncology, 2015-11, Vol.16 (15), p.e527-e527
issn 1470-2045
1474-5488
language eng
recordid cdi_proquest_miscellaneous_1751203132
source Elsevier
subjects Birth control
Breast cancer
Contraceptives, Oral - adverse effects
Endometrial cancer
Endometrial Neoplasms - epidemiology
Estrogens - adverse effects
Female
Health risk assessment
Hematology, Oncology and Palliative Medicine
Humans
Progestins - adverse effects
Womens health
title Endometrial cancer with progestagen and oestrogen oral contraceptives
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-22T16%3A51%3A28IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Endometrial%20cancer%20with%20progestagen%20and%20oestrogen%20oral%20contraceptives&rft.jtitle=The%20lancet%20oncology&rft.au=Grant,%20Ellen%20C%20G&rft.date=2015-11&rft.volume=16&rft.issue=15&rft.spage=e527&rft.epage=e527&rft.pages=e527-e527&rft.issn=1470-2045&rft.eissn=1474-5488&rft.coden=LANCAO&rft_id=info:doi/10.1016/S1470-2045(15)00278-8&rft_dat=%3Cproquest_cross%3E3860725221%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c4438-7c970c084d5a80ec567b95bfe15c6343ba0ee16c51a40f9babe04cc0e4db87533%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1731819138&rft_id=info:pmid/26545838&rfr_iscdi=true